| Literature DB >> 32705544 |
Joaquim Vives1,2,3, Luciano Rodríguez4, Maria Isabel Coca4, Laura Reales4, Raquel Cabrera-Pérez4,5, Lluís Martorell4,5.
Abstract
Tissue engineering products (TEP) are a new type of medicines resulting from the combination of cells, scaffolds, and/or signalling factors, which can be used for the regeneration of damaged tissues thus opening new avenues for the treatment of complex conditions. However, such combination of biologically active elements, particularly living cells, poses an unprecedented challenge for their production under pharmaceutical standards.In the methods presented here, we formulated two types of TEP based on the use of multipotent mesenchymal stromal cells with osteogenic potential combined with osteoinductive and osteoconductive bony particles from tissue bank embedded in a fibrin hydrogel that, altogether, can induce the generation of new tissue while adapting to the diverse architecture of bony defects. In agreement with pharmaceutical quality and regulatory requirements, procedures presented herein can be performed in compliance with current good manufacturing practices and be readily implemented in straightforward facilities at hospitals and academic institutions.Entities:
Keywords: Bone; Cell-based therapy; Fibrin glue; Good manufacturing practice; Multipotent mesenchymal stromal cells; Regenerative medicine; Scaffold; Tissue engineering product
Year: 2021 PMID: 32705544 DOI: 10.1007/7651_2020_280
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745